Proteon Therapeutics, Inc. (NASDAQ:PRTO) released its earnings results on Monday. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.11, Bloomberg Earnings reports.

Shares of Proteon Therapeutics (PRTO) traded up 3.85% during mid-day trading on Wednesday, reaching $1.35. 9,254 shares of the company traded hands. The stock’s market capitalization is $22.64 million. The firm has a 50 day moving average of $1.38 and a 200-day moving average of $1.57. Proteon Therapeutics has a 52 week low of $1.10 and a 52 week high of $11.45.

TRADEMARK VIOLATION WARNING: “Proteon Therapeutics, Inc. (PRTO) Releases Earnings Results, Beats Expectations By $0.11 EPS” was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at

PRTO has been the topic of a number of recent research reports. Cowen and Company reaffirmed a “hold” rating on shares of Proteon Therapeutics in a research report on Tuesday. HC Wainwright set a $3.00 target price on shares of Proteon Therapeutics and gave the stock a “hold” rating in a research report on Saturday, May 13th. Zacks Investment Research downgraded shares of Proteon Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Maxim Group set a $6.00 target price on shares of Proteon Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Earnings History for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with's FREE daily email newsletter.